DESCRIPTION
WARNING
| Use In
Pregnancy: When used in pregnancy during
the second and third trimesters, drugs that act directly
on the renin-angiotensin system can case injury and
even death to the developing fetus. When pregnancy
is detected, losartan potassium should be discontinued
as soon as possible. See WARNINGS, Fetal/Neonatal/Morbidity
and Mortality. |
Losartan potassium, the first of a new class of antihypertensives,
is an angiotensin II receptor (type AT1) antagonist.
Losartan potassium, a non-peptide molecule, is chemically
described as 2-butyl-4-chloro-1[p-(o-1H-tetrazol-5- ylphenyl)benzyl]imidazole-5-methanol
monopotassium salt.
Its empirical formula is C22H22ClKN6O.
Losartan potassium is a white to off-white free flowing
crystalline powder with a molecular weight of 461.01.
It is freely soluble in water, soluble in alcohols, and
slightly soluble in common organic solvents, such as acetonitrile
and methyl ethyl ketone. Oxidation of the 5-hydroxymethyl
group on the imidazole ring results in the active metabolite
of losartan.
Cozaar is available for oral administration containing
either 25 mg or 50 mg of losartan potassium and the following
inactive ingredients: microcrystalline cellulose, lactose
hydrous, pregelatinized starch, magnesium stearate, hydroxypropyl
cellulose, hydroxypropyl methylcellulose, titanium dioxide,
D&C yellow No. 10 aluminum lake and FD&C blue
No. 2 aluminum lake.
Cozaar 25 mg and 50 mg contain potassium in the following
amounts: 2.12 mg (0.054 mEq) and 4.24 mg (0.108 mEq) respectively.
|
|
